key: cord-0774301-5dnlo1iu
authors: Patnaik, Mrinal M.; Lasho, Terra; Padron, Eric; McCullough, Kristen; Al‐kali, Aref; Tefferi, Ayalew; Zeidan, Amer M.; Gangat, Naseema; Savona, Michael; Steensma, David P.; Solary, Eric
title: Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS‐CoV‐2 pandemic
date: 2020-05-22
journal: Am J Hematol
DOI: 10.1002/ajh.25853
sha: 4e106af1972ebaefc842c94fe42f7639de4acfc6
doc_id: 774301
cord_uid: 5dnlo1iu

nan

receptor to gain entry into cells, with these receptors widely expressed in the cardiopulmonary system, monocytes and monocyte-derived macrophages. 4 Monocytes and macrophages frequently interact with ACE2-expressing cells in various tissues, and ACE2 is also expressed by cells of the bone marrow (BM) niche, where it associates with the granulocyte-colony stimulating factor (G-CSF) receptor to negatively regulate hematopoietic progenitor cells mobilization (supplemental material for complete reference list in Data S1).

The cytokine profile of patients with COVID-19 resembles that of patients with secondary hemophagocytic lymphohistiocytosis (HLH), with the excess production of interleukin 2 (IL-2), IL-6, G-CSF, interferon gamma inducing protein 10, monocyte chemoattractant protein-1 and tumor necrosis factor (TNF) alpha, among others. 5, 6 Severe manifestations of SARS-CoV-2 are largely cytokine mediated and include cytokine release syndrome (CRS), respiratory failure secondary to acute respiratory distress syndrome (ARDS), and multiorgan dysfunction syndrome (MODS) ( Figure S1 ). 1, 2, 5 Note, IL-6 is a prominent secreted cytokine and plays a critical role in the inflammatory cascade seen. 6 This has led to the use of IL-6 and IL-6 receptor (IL-6-R)-directed monoclonal antibodies such as siltuximab (IL-6) and tocilizumab/sarilumab (IL-6-R) in the management of CRS and ARDS in patients with COVID-19. (Table 1) .

Permissive leukocytosis in these pateints to a degree that may be reasonable in other settings may put patients at increased risk for complications in the COVID-19 era, and tighter regulation of the WBC is a worthwhile consideration. This has to be carefully balanced with the potential need for additional blood draws and clinic visits, antagonists' being superior to IL-6 neutralizing antibodies, due to the ability of the former in blocking trans presentation of IL-6, an important mechanism in the development of acute lung injury and ARDS. 13 Preliminary data from China in SARS-CoV-2 with tocilizumab seems encouraging, with oxygen requirements being reduced in 75% of tocilizumab-treated patients (n = 21). Clinical trials with sarilumab and siltuximab continue to accrue.

Given the inherent hypersensitivity of CMML cells to GM-CSF (granulocyte macrophage), additional anti-cytokine therapy using anti-GM-CSF monoclonal antibodies such as lenzilumab may also be considered. Of note, lenzilumab has been shown to abrogate neurotoxicity and CRS by neutralizing GM-CSF in chimeric antigen receptor T-cell mice models. 14 In addition, a recent phase 1 study of lenzilumab in CMML demonstated clinical benefit in 27% of patients, without any drug-related grade 3 or 4 adverse events. 10 Mavrilimumab, a GM-CSF receptor alpha directed mononclonal antibody is also being considered for the management of CRS in SARS-CoV-2. Additional cytokinedirected clinical trials that might have value in the context of SARS-CoV-2 induced CRS include studies with anakinra (IL-1beta receptor antagonist), empalumab (monoclonal antibody to interferon gamma, currently approved for HLH) and JAK inhibitors (ruxolitinib, pacritinib) ( Table 1) . We continue to closely watch these studies for safety and efficacy signals. We recommend that all providers consider documenting any patients with hematological malignancies infected with SARS-CoV-2 in the American Society of Hematology (http:// www.ashresearchcollaborative.org/covid-19-registry) and COVID19

and Cancer Consortium (CCC19 http://ccc19.org) registries.

et al; China Medical Treatment Expert Group for Covid-19Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of COVID-19 in New York city

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Cytokine release syndrome in severe COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and immunological features of severe and moderate coronavirus disease 2019

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML

Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML). Blood

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations

Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6

Targeting Interleukin-6 Signaling in Clinic

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Current publication is supported in part by grants from the "The